

CureVac AG · Friedrich-Mescher-Str. 15 · 72076 Tübirgen, Germany

European Commission Rue de la Loi 200/ Wetstraat 200 1049 Bruxelles/Brussel Belgium T +49 7071 F +49 7071 Page 1

FOLLOW UP LETTER TO

Dear

Please allow me to thank you for your time and drive in the recent discussions CureVac had with the European Commission on the development of our SARS-CoV-2 vaccine.

In these discussions, the Company
This letter aims at detailing the

1.

As previously discussed, the

CureVac is moving into In parallel, CureVac

The demand and competition for

those

The Company is

In exchange, CureVac

While many variables

Cure Vac AG

Friedrich Miescher Strasse 15 72076 Tübingen, Germany T +49 7071 9683-0 F +49 7071 9883-1101 info@curevac.com www.curevac.com

Management Board

Dr. Ingmar Hoerr (Chairman), Dr. Franz-Werner Haas, Dr. Maricia Fohn Mieczek Dr. Florian von der Mülbe, Pierre Kemula

Chairman of the Supervisory Board

Jean Stéphenne

Registered Seat

Local Court Stuttgart HRB 754041



	This cose range is based on the Company's preclinical results showing very high neutralization with its optimized mRNA construct. In contrast, Moderna announced that it
	will test doses of 50µg and 100µg.
U	The Company is ready to
	Of note, recent publications of OXFORD results or the Chinese Beijing institute on adenovirus do not show promising results in humans and demonstrate that adjuvanted-proteins and mRNA are more promising technologies, inducing high neutralization titers.
2.	
	Assuming the optimum dose determined in the clinical trial is this represents a
	In the short run. CureVac will present the vaccine in
	Additional discussions
	In our recent exchanges, we were referring to the
-	



3.				
I trust this properly summarises the situation we have all discussed and formalises the				
I am looking forward to exchanging at your earliest convenience,				
Yours Sincerely,	204			